Cargando…
In silico prediction of mozenavir as a potential drug for SARS-CoV-2 infection via binding multiple drug targets
Since the epidemic began in November 2019, no viable medicine against SARS-CoV-2 has been discovered. The typical medication discovery strategy requires several years of rigorous research and development as well as a significant financial commitment, which is not feasible in the face of the current...
Autores principales: | Mamidala, Estari, Davella, Rakesh, Praveen Kumar, Munipally, Swamy, Satyanarayana, Abhiav, Mruthinti, Ali Kaimkhani, Zahid, Al-Ghanim, K.A., Mahboob, Shahid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522677/ https://www.ncbi.nlm.nih.gov/pubmed/34690521 http://dx.doi.org/10.1016/j.sjbs.2021.10.023 |
Ejemplares similares
-
Evaluation of the andrographolides role and its indoleamine 2,3-dioxygenase inhibitory potential and attendant molecular mechanism against STZ-induced diabetic rats
por: Kumar, Munipally Praveen, et al.
Publicado: (2020) -
Phenolic compounds as promising drug candidates against COVID-19 - an integrated molecular docking and dynamics simulation study
por: Davella, Rakesh, et al.
Publicado: (2022) -
Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug
por: Ameen, Fuad, et al.
Publicado: (2021) -
Tangeretin ameliorates bisphenol induced hepatocyte injury by inhibiting inflammation and oxidative stress
por: Ijaz, Muhammad Umar, et al.
Publicado: (2022) -
Pachypodol attenuates Perfluorooctane sulphonate-induced testicular damage by reducing oxidative stress
por: Umar Ijaz, Muhammad, et al.
Publicado: (2022)